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Abstract
Background: A growing body of evidence shows the short-term benefits of breastfeeding, which include protection
against infections, allergies, and lung diseases. However, evidence on the long-term benefits of breastfeeding is scarce
and often conflicting. The BReastfeeding Attitude and Volume Optimization (BRAVO) trial is designed to study the
effect of breastfeeding on early signs of later chronic diseases, particularly cardiovascular, respiratory, and metabolic
risks later in life. In addition, the effectiveness of breastfeeding empowerment in promoting breastfeeding will also be
evaluated.
Methods/design: This study is an ongoing randomized trial in Jakarta, Indonesia, that began in July 2012. Pregnant
women are being screened for their breastfeeding plan in the third trimester, and those with low intention to
breastfeed are randomly allocated to either receiving an add-on breastfeeding-optimization program or usual care.
Primary outcomes include breastfeeding rate, lung function, and blood pressure during the first year of life and
vascular/cardiac characteristics, which will be measured at the age of 4 to 5 years. Child growth and infection/illness
episodes are measured, whereas cognitive testing is planned for the children at 5 years of age.
Discussion: To date, 784 women (80 %) have been randomized of the 1,000 planned, with satisfactory completeness
of the 1-year follow up (90.1 %). Included mothers are of lower socioeconomic status and more often have blue-collar
jobs, similar to what was observed in the pilot study.
Trial registration: ClinicalTrials.gov, NCT01566812. Registered on 27 March 2012.
Keywords: Breastfeeding, Trial, Breastfeeding empowerment, Breastfeeding rate, Carotid artery wall intima-media
thickness (CIMT), Arterial stiffness
Background
The World Health Organization (WHO) aims to have
newborns exclusively breastfed for 6 months [1]. How-
ever, it is estimated that globally only 38 % of infants are
exclusively breastfed, and every year, 800,000 deaths
among children under 5 years of age have been
attributed to suboptimal breastfeeding [2]. These acute
consequences are urgent, but concern has existed for de-
cades that suboptimal breastfeeding may have lifelong
health implications as well.
Breastfeeding is suggested to protect against infections,
allergies, and lung disease, as well as overweight and obes-
ity [3, 4], diabetes mellitus [5], cardiovascular risk factors
[6, 7], and cardiovascular diseases [8, 9]. Such suggestions
draw heavily on nonexperimental research in which, espe-
cially with breastfeeding, confounding bias is a major
issue. Human breastfeeding experimentation in a fully ex-
planatory way is impossible due to firm public and care
preferences and strong adherence to WHO recommenda-
tions, and given a lack of equipoise for at least short-term
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benefits [10, 11]. However, numerous pragmatic random-
ized experiments had been done, primarily aimed to pro-
long breastfeeding duration, using a range of prenatal
and/or postnatal interventions with different randomized
designs and in a large variety of settings and populations
[12–34]. By far, the largest and probably most informative
is a cluster-randomized trial, the Promotion of Breastfeed-
ing Intervention Trial (PROBIT), in over 17,000 women
in Belarus, which showed that empowerment raised
breastfeeding rates and decreased infant gastrointestinal
infection and atopic eczema rates, thus clearly underpin-
ning short-term benefits [35]. However, later nonrando-
mized analyses on that trial did not show protection
against obesity and high blood pressure [36–38], allergies
and asthma [39], and behavior problems [40].
Indonesia is a low-income to middle-income country
with a population of 250 million and 4 to 4.5 million
births per year. Indonesia lags behind WHO recommen-
dations with only 15 to 40 % exclusively breastfeeding
[41–43]. Indonesia is experiencing an epidemiological
transition, and it is among the regions identified to face
a strong rise in noncommunicable diseases, including
atherosclerotic disease and a significant prevalence of
chronic obstructive pulmonary disease [44, 45]. Much
potential exists for an improvement of breastfeeding
practices, as breastfeeding empowerment programs have
been shown effective in various Southeast (SE) Asian
countries, although not in Indonesia [46–48]. Modifiable
predictors of nonexclusive breastfeeding in SE Asian
countries have been identified and include the absence
of prenatal breastfeeding planning, working by mothers,
and the noninvolvement of fathers in the breastfeeding
planning [49]. Generally, breastfeeding-promotion pro-
grams are probably more successful in achieving exclu-
sive breastfeeding in lower income countries like
Indonesia than in economically more affluent societies
[50]. Nevertheless, due to the specific local mix of cul-
tures, religions, ethnic backgrounds, and limited re-
sources, the effectiveness of empowerment programs
that worked elsewhere, even in SE Asia, cannot be taken
for granted in Indonesia.
A new randomized breastfeeding trial is currently being
conducted in Jakarta, Indonesia. The Breastfeeding Attitude
and Volume Optimization (BRAVO) trial (clinicaltrials.gov
NCT01566812) aims to individually randomize 1000
women in later pregnancy, when decision making about
breastfeeding is imminent. In a pilot study, a stepped-
screening procedure for eligibility was tested in 207 preg-
nant women, of whom 56 % intended to breastfeed less
than 2 months, and 38 % were willing to be randomized
[51]. Like virtually all reported breastfeeding empowerment
trials, BRAVO questions whether breastfeeding can be opti-
mized toward WHO recommendations. However, in
BRAVO, the principal aim is to study breastfeeding effects
on early life signs of later life cardiovascular and cardiomet-
abolic risks, and respiratory risks that have become particu-
larly pressing in Indonesia [42, 52]. This aim has led us to
choose individual rather than the commonly used cluster
randomization for intensive individual prenatal and postna-
tal empowerment intervention for maximal breastfeeding
contrasts, and to choose a trial size and measurements spe-
cifically aimed at the detection of cardiovascular, cardiore-
spiratory, and cardiometabolic effects in early childhood.
BRAVO aims to measure the effects of breastfeeding on
the developing cardiovascular organ system itself.
To date, BRAVO has included and randomized 780
pregnant women in their third trimester. The BRAVO de-
sign is herein presented, along with a cross-sectional de-
scription of both the screened and enrolled populations.
Methods/design
Study design and setting
BRAVO is a pragmatic, parallel, group-randomized trial
that began in July 2012. The report of this study proto-
col was made conforming to the SPIRIT 2013 Statement
(Standard Protocol Items: Recommendations for inter-
ventional trials) [53] (see Additional file 1). The study
process is illustrated in Fig. 1.
During pregnancy, eligible women are randomly allo-
cated either to receive a program aimed at add-on
breastfeeding optimization during pregnancy and the
first 6 months after delivery or to receive primary care
as usual. After randomization, a first cardiovascular as-
sessment will be made when the children are between 4
and 5 years of age.
Women under primary or referred care are screened for
eligibility. Women are recruited from Budi Kemuliaan Hos-
pital, a private specialized referral center for maternal and
child care in the municipality of Jakarta (Director MB),
which has a delivery rate of 7,000–8,000 newborns/year. It
performs service delivery, training (midwives), education,
and research. The hospital has ten staff members with Good
Clinical Practice certificates. The attending women are
partly mobile, but many live in the vicinity and have the hos-
pital as first choice. Budi Kemuliaan features a home-visit
program by midwives in training. Restriction to women with
Budi Kemuliaan as first choice ensures some 3,000/year for
inclusion. Women are also recruited from local primary care
centers, including primary care centers in the Senen and
Jatinegara districts. This study was ethically approved by the
Institutional Review Board of the Faculty of Medicine Uni-
versity of Indonesia/Cipto Mangunkusumo General Hospital
(reference number: 913/UN2.F1/ETIK/X/2015).
Stepped eligibility screening, recruitment, and informed
consent
BRAVO has a stepped-screening procedure for eligibil-
ity, of which the details, including the inclusion criteria,
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are given in Table 1. Criteria for eligibility include preg-
nant women under primary or referred healthcare who
intend to breastfeed their newborn shortly or not at all.
Midwives or primary care workers in charge of routine
pregnancy care do the recruitment during visits. Informed
consent will be obtained from all participants. Eligible
women are first informed about BRAVO and, then, are
formally invited to participate. Women are given 1 week
to decide and are asked to inform their midwives or pri-
mary care physicians about their decision at the next visit
or by telephone calls if they have then not decided yet.
Women who decide to participate are asked to sign a
BRAVO informed consent form (see Additional file 2).
Pilot study
Prior to BRAVO, a pilot study was conducted to assess
the feasibility of the procedures related to the screening,
invitation, informed consent, and randomization (see
Background). The pilot focused on the active roles of the
midwives and primary care physicians, both from a prac-
tical and theoretical viewpoint. Women were subjected to
procedures for antenatal and postnatal breastfeeding sup-
port as planned (see Interventions). Experiences of women
and caretakers were registered and used for fine-tuning of
the empowerment intervention. As caretakers are respon-
sible for both BRAVO conduct and future empowerment
implementation, their needs and comments were max-
imally accommodated.
Interventions
1. Care as usual
Care as usual means that there is no interference
with breastfeeding propagation practice in current
Fig. 1 Flowchart of the study process. SMS, short message service; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-like growth factor binding globulin 3
Savitri et al. Trials  (2016) 17:271 Page 3 of 10
Indonesian care, which, in general, follows the
WHO recommendations for successful breastfeeding.
The implementation of these recommendations varies
across hospitals and primary care centers according to
resource availability. Generally, education about
breastfeeding is given individually by attending
midwives or physicians during antenatal visits.
2. Breastfeeding empowerment
Randomized trials in Southeast Asia have shown that
empowerment effectively raises exclusive breastfeeding
rates [47]. For BRAVO, these programs were adapted
in both language and culture to the Indonesian setting.
Clearly, optimal empowerment comes from both
antenatal and postnatal intervention [47]. The BRAVO
program consists of antenatal, perinatal, and postnatal
intervention, and special supports for working
mothers, including the provision of breast pump
equipment when necessary and active support at
workplaces. A lactation manager coordinates breast
pump provision and gives written advocacy to
employers to provide a lactation room and working
hours that allow mothers to express their breast milk.
During late pregnancy, women in the intervention
group are subjected to one private and one
group-counseling session. To avoid intervention
contamination, the antenatal visit in the empowerment
intervention is handled by a particular group of
midwives or primary care physicians who underwent
a standardized breastfeeding-counseling training
during BRAVO preparation, while the care-as-usual
group members have routine antenatal visits to regular
caretakers. At private counseling, conducted within
28–37 weeks of gestational age, women and families
are enabled to visit a lactation counselor for 30 minutes,
mainly to build motivation for breastfeeding. A set of
leaflets addressed specifically to mothers, husbands, or
grandmothers is given at the end of the session.
At group counseling, women are subjected to a
commercially available video (http://injoyvideos.-
com/) based on a 16-minute educational video entitled
“14 steps to better breastfeeding” (Injoy Videos, Boulder,
CO). The video is voiced over in Indonesian language
and demonstrates correct positioning, latch on, and
breast care. Closest family members (husband and/or
women’s mother) are also invited to watch the video.
Group counseling also allows mothers to share opinions
with peers and mutual encouragement.
Empowerment intervention continues around
delivery. Apart from early initiation and lactation
support as part of routine care in Budi Kemuliaan
Hospital and primary care centers, the intervention
arm receives one extra home visit from appointed
midwives/breastfeeding counselors to establish
breastfeeding, address problems, and check
preparations at home.
As part of the postnatal intervention, women in the
intervention group are visited at home by caretakers
within the first postnatal week, both with usual care
and experimental lactation support. A second
lactation support visit takes place within week 1–2
after delivery. Thereafter, midwives and primary care
workers have telephone contact once in 2 weeks in
the first month and once a month thereafter for
lactation support until 6 months after delivery. A
centrally managed, regular, short message service
(SMS) to encourage breastfeeding practice is sent
weekly. A breastfeeding hotline or call center
managed by midwives is set up to anticipate urgent
questions or problems of the mothers. Mothers in
the intervention group who return to work before
6 months after delivery receive additional counseling
on preparing, storing, and feeding their babies with
expressed breast milk. Also, letters are written to
formally advocate for the mothers’ employer to
facilitate breastfeeding continuation by providing
secluded space, working hours, and environments
that allow for expressing breast milk. A breast-milk
pump rental is arranged on request.
Trial retention
To promote trial retention, all mothers, irrespective of
the intervention arm, receive reimbursement for their
travel expenses to the primary health care or research
hospital, and infants who are not covered by government
Table 1 BRAVO eligibility screening steps during gestation
Step Purpose
1 Plans breastfeeding Gestation week 28–36: midwives provide
a short questionnaire to measure plans
for breastfeeding duration
≤ 2 months
2 to≤ 4 months
4 to≤ 6 months
> 6 months
Women indicating≤ 2 months are eligible
2 Stability residence From the group of women that were selected
under Step 1, a further selection is made of
those living in the vicinity of the hospital
3 Inclusion criteria 1. Residing in vicinity of participating
hospital or primary care centers
2. Telephone communication possible with
mother, concerning present pregnancy
3. Uncomplicated (no morbidity requiring
hospitalization or intensive care,
e.g., eclampsia)
4. No major fetal congenital disease
5. No known HIV in mother
4 Passed steps 1–3 Formal invitation of women to participate
in BRAVO
Women who, after randomization, have babies that are stillbirth, of premature
birth (birth weight < 2500 g, gestational age < 37 weeks), or have congenital
heart disease or multiple congenital anomaly are not excluded and will be
part of the intention-to-treat analysis
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health insurance obtain free basic immunization. Investi-
gators also set up a stepwise standard procedure for
mothers who do not turn up for the routine health
check; this procedure includes at least two telephone re-
minders and home visits if mothers were not able to
come for the outcome measurement.
Baseline trial measurements
Table 2 shows the baseline parental and child character-
istics that are measured in BRAVO.
Endpoints
BRAVO deals with studying every child’s first year; in
addition, it will follow children until at least their 5th
year of life for carotid artery wall measurements, pul-
monary function, anthropometry, and disease history. A
general scheme of measurements and timing throughout
BRAVO follow-up is presented in Table 3. Outcome as-
sessors and data analysts are being blinded about the
participants’ assignment to interventions. Retention of
mothers and children at the age of 5 years will be opti-
mized by proactively contacting the mothers by tele-
phone or in writing.
Primary outcome I includes the monthly question-
naire/telephone call to discuss feeding patterns (breast/
formula feeding habits).
Primary outcome II includes the vascular wall character-
istics at 4 years old (thickness of carotid intima-media,
distensibility, and elastic modulus) (see Table 4).
The secondary outcomes include the blood pressure,
lung function/respiratory tract disease, infection, allergy,
obesity, growth and development, cardiac function, breast-
milk analysis (especially the fat content), and the gut/air-
way microbiome.
For subjects who discontinue or deviate from the
study protocol but still live in the Jakarta area, home
visits are conducted to collect data for breastfeeding
habits, history of illness in the past 1 month, and growth
data taken from the infant health card.
Data management, randomization, statistical power, and
data analysis
All trial data are gathered through web-based data entry
sheets (www.bravo-trial.com) by research nurses/assistants.
Data management is the responsibility of the Department
of Child Health/Center for Clinical Epidemiology and
Evidence-Based Medicine (CEEBM) Faculty of Medicine
University of Indonesia/Cipto Mangunkusumo National
General Hospital in Jakarta, Indonesia. All investigators
who belong to the BRAVO study group have access to the
final trial database through the data manager (SRFS). Local
principal investigators (NSI, WI) are also granted direct ac-
cess to the trial database for monitoring. Public availability
of clinical trial data is a pending debate [54] and until
decided, any BRAVO data usage is decided by consensus of
the BRAVO study steering committee (NSI, CSPMU, SS,
WI, and DEG). Randomization is centrally performed using
computer-based random lists for simple parallel groups.
All participating women are given individual study num-
bers, and their personal information is collected, shared,
Table 2 Baseline characteristics of the parents and of the
child’s birth
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and maintained in order to protect confidentiality before,
during, and after the trial.
BRAVO is restricted to pregnant women who, from
their own free will, plan to give breastfeeding for no lon-
ger than 2 months, if at all. Forty percent of all pregnant
women were estimated to meet that criterion. Thus, for
every four eligible women, 10 pregnant women have to
be screened, assuming that the number of women lost
to exclusion is negligible. The effect of the empower-
ment program on the increase of exclusive breastfeeding
was the first required estimate. From a Southeast Asian
trial that used no restrictions on women’s plans to
breastfeed for short times, exclusive breastfeeding pro-
portions in the experimental group were expected to be
at least 1.5 times higher than in the care-as-usual group.
This relative risk was reported throughout the first 6
Table 3 Schedule of enrollment, interventions, and assessments
Study period
Enrollment Allocation Post-allocation Close-out
TIME POINT Gestation week Birth month







Postnatal home visit X
Biweekly postnatal contacts
Postnatal visits X X X X X X
Telephone calls X X X X X X X X X X X X
SMS X X X X X X
ASSESSMENTS:
Maternal ad family data X
Lung function SOT X X
Lung spirometry X X
Feces sampling X X X X X X
Breastmilk sampling X X X X X X
Diary upper/lower RTD, allergy, infections X X X X X X X X X X X X X
Blood pressure measurement X X X X X X X
Anthropometry X X X X X X X
Vascular US carotid artery test X
Pulse-wave velocity/stiffness X
Echocardiography cardiac function X
IGF-1, IGFBP-3, leptin levels, fibrinogen* X X
SMS short message service, SOT single occlusion technique, RTD respiratory tract disease, US ultrasound, IGF-1 insulin-like growth factor 1, IGFBP-3 insulin-like
growth factor binding globulin 3
Table 4 Cardiovascular endpoint measurements
Methods Arterial segment Timing
Vascular ultrasound Carotid artery 48 to 60 months
Arterial stiffness: pulse wave velocity, augmentation index Arteriography 48 to 60 months
Blood pressure Oscillometric device Brachial artery 2, 4, 6, 9, and 12 months,
48 to 60 months
Cardiac function: cardiac output, LV systolic/diastolic function, RV diastolic function Echocardiography - 48 to 60 months
LV left ventricle, RV right ventricle
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neonatal months but decreased from 83 % to 53 % at
14 days postpartum and ultimately to 20 % in the experi-
mental group, and to 0 % in the usual-care group at
6 months. In 5-year-old healthy children, breastfeeding
versus formula feeding was suggested to have an effect
on carotid artery wall intima-media thickness of 20 μm,
at an average CIMT of 386 μm (SD 37). Translating to
BRAVO, a comparison of 54 women in an exclusive
breastfeeding group and 54 women in an exclusive
bottle-feeding group would allow detection of a 20-μm
group difference in carotid IMT, with 80 % power and
alpha = 0.05. Obviously, BRAVO does not yield random-
ized groups of exclusive breastfeeding and exclusive
bottle-feeding groups. Due to contemporary uncertain-
ties about the effects of empowerment on breastfeeding
and ultimately on the cardiovascular system, it was as-
sumed that a group that was at least ten times bigger was
to be randomized. BRAVO, therefore, aimed to randomize
1000 eligible pregnant women, requiring screening of ap-
proximately 2500 pregnant women. A trial of 1000 women
can detect small differences in breastfeeding practices be-
tween intervention groups. An estimated 500 women ran-
domly allocated to each group would allow for the
statistical detection of a nominal difference of almost 10 %
in exclusive breastfeeding proportions, with 90 % power
and a statistical significance level of 0.05 (PASS 2008).
From a public health point of view, a difference of 10 % or
higher was considered meaningful.
With respect to data analysis, both descriptive and
baseline prognostically important characteristics will be
tabulated against intervention strategy. The chance of
successful exclusive breastfeeding for 6 months (yes/no)
will be compared between the empowerment and care
as usual group by calculating the relative risk with 95 %
confidence intervals. As an absolute risk estimate to sup-
port public health policy making, the number needed to
treat (by breastfeeding empowerment) and 95 % confi-
dence intervals will be calculated. The duration of
breastfeeding will be studied as a function of the inter-
ventions by using linear regression with (transformed)
duration as the dependent variable and a group indicator
as the independent variable. Should there be post-
randomization differences that would hamper proper in-
terpretation, regression modeling will be used to adjust
all findings for baseline prognosis (propensity score or
inverse probability weighting techniques).
The effects of intervention on cardiovascular measure-
ments will be studied using linear regression techniques
with cardiovascular measurements as the dependent vari-
ables and a group indicator variable as the independent
variable. All regression models will also be used for adjust-
ing for baseline noncomparability when necessary. All ana-
lyses will be performed according to the intention-to-treat
principle, such that all randomized women will be
analyzed by their randomized allocation. Possibly, biased
missingness of the 5-year outcome data will be assessed
using additional tables of baseline data comparing the
available and missing data, and the above-described analyt-
ical techniques will be applied for dealing with prognostic
group differences [55]. Missing data will be analytically ad-
dressed using multiple imputation regression techniques.
Results of screening, enrollment, and preliminary follow-up
Table 5 shows the characteristics of women who were
screened for BRAVO. The ages of the included and ex-
cluded women were similar. Included women were more
often of low socioeconomic status. Although there was no
statistically significant difference in the proportion of
working mothers between the excluded and included
women, included women more often had blue-collar em-
ployment. So far, the 1-year follow-up is 90.1 % complete.
Discussion
To our awareness, BRAVO is the first randomized breast-
feeding empowerment study that is specifically focused on
estimating the early life cardiovascular and cardiometa-
bolic consequences of breastfeeding. Currently, at almost
80 % of the intended enrollment, the first part of BRAVO
has been shown feasible and highly successful.
A strong feature of BRAVO is the number of individually
randomized pregnant women; to our knowledge, this trial
is one of the larger of its kind in a low-resource setting.
The principal aim of BRAVO, which is to study the effects
of breastfeeding on the early life development of cardiovas-
cular function and structure, sets it apart from other trials
that were primarily designed to measure the effects of
empowerment on breastfeeding proportions. A major
Table 5 Characteristics of screened women (n = 1234)
Excluded N = 707 Included N = 527 P value
Age 31.3 (5.7) 30.3 (5.9) 0.301
Socioeconomic status <0.0012
Low 78 (12.7) 117 (22.9)
Middle 432 (70.5) 358 (70.1)
High 103 (16.8) 36 (7)
Number of pregnancy 0.702
1 233 (37.8) 212 (41.2)
2 218 (35.3) 173 (33.7)
3 112 (18.2) 87 (16.9)
>3 54 (8.8) 42 (8.2)
Working mother 213 (34.6) 152 (29.7) 0.082
Blue-collar job 49 (23.9) 55 (37.7) 0.0062
Previous breastfeeding 310 (43.8) 248 (47.1) 0.142
Values are means with standard deviations for continuous variables and percentages
for frequencies. In case of skewed data (*), the median with the interquartile range
was presented
1Independent samples t-test, 2Chi-Square test
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challenge in trials is to achieve accurate and complete
follow-up. This is particularly challenging in BRAVO, as it
deals with young families in a highly mobile culture. In
BRAVO, the follow-up, to be done for the first year of life,
is designed to follow regular care (vaccination scheme), is
proactive, and includes home visits. So far, follow-up com-
pleteness is satisfactory, although the final results will have
to be awaited. BRAVO, like all other breastfeeding trials, is
pragmatic, so its ultimate success depends on the contrast
in breastfeeding between intervention arms that can be
achieved. This contrast will still be a function of distribu-
tions of breastfeeding duration in both arms and, import-
antly, on the distributions of bottle and other infant feeding
in both arms. Obviously, BRAVO registers breastfeeding
duration in both arms as well as the introduction of other
feeding habits. The fact that BRAVO, as with other trials,
can only study cardiovascular effects as a function of the
overall breastfeeding contrast is a limitation that cannot be
circumvented by design. On the other hand, the pragmatic
character of BRAVO will allow for easier implementation
of beneficial results, if found. In principle, a threat to the
BRAVO design is that women who are randomly allocated
to care as usual will, knowing about the study objectives,
change their breastfeeding plans, thus leaving a smaller
contrast between the experimental intervention arms. An
alternative would have been pre-randomization (first
randomize, then obtain informed consent), such as
done in Zelen’s design [56]. However, since BRAVO focuses
on women who during pregnancy have already planned to
provide for a maximum period of 2 months breastfeeding,
pre-randomization, with its associated medical ethical impli-
cations, was not considered necessary. In BRAVO, individ-
ual women are randomized, rather than clusters of women
within, for instance, primary care practices. Monitoring of
breastfeeding motivation takes place on an individual basis
and is performed by the study nurses. The effects of close
monitoring are not expected to go easily for all pregnant
woman. Although, in principle, a risk of intervention con-
tamination exists, BRAVO uses individual rather than clus-
ter randomization for a couple of reasons. First, the full
intervention, both prenatal, perinatal, and postnatal, is well
outside the realm of usual care, as it requires high levels of
organization (group counseling, home visits). Although
cluster randomization was considered, only limited num-
bers of clusters were feasible in the BRAVO setting, which
would have substantially increased the chance of baseline
prognostic noncomparability, a much bigger threat to the
overall purposes than contamination. A cluster-randomized
design would have required larger numbers of pregnant
women, in whose offspring highly specialized cardiovascular
and respiratory measurements were considered unfeasible.
Finally, a cluster-randomized design bears intrinsic prior
uncertainties, such as ultimately achieved (differences in)
cluster sizes and unknown within-cluster correlations.
Although such variation can be dealt with in analysis, the
BRAVO design with individual randomization was consid-
ered a priori a more robust approach, specifically concern-
ing its overall aim, the study of cardiovascular and
cardiometabolic consequences of breastfeeding.
Obviously, breastfeeding randomization with its claimed
beneficial health outcomes can only be considered within
certain ethical boundaries. In principle, BRAVO does not
interfere with current practice and personal maternal
choices regarding children’s nutrition; instead, it applies a
breastfeeding intervention that is meant to improve
breastfeeding practices. As alluded to above, many exam-
ples exist of such randomized breastfeeding empower-
ment studies, including in (Southeast) Asian countries
[48]. The ethical justification of such trials has been uncer-
tainty or equipoise with regard to the effectiveness of em-
powerment programs on breastfeeding rates. As in the
Indonesian setting, where the effectiveness is currently un-
known, it is uncertain whether Indonesian women allo-
cated to care as usual are withheld better care, and
whether an alternative of empowerment is better is simply
unknown. Therefore, as there is equipoise, randomization
is considered justified. Moreover, women in BRAVO are
selected such that they, by their own choice, plan to pro-
vide breastfeeding for a maximum of 2 months, if at all. If
BRAVO were not conducted, all pregnant women would
receive no empowerment other than that currently avail-
able under care as usual.
The first results of BRAVO show that some 40 % of
screened women participated in BRAVO, which is
slightly above the expected number. The enrolled and
randomized women were more often of low socioeco-
nomic status and more often had blue-collar employ-
ment, since they were more likely to have no plans for
extended breastfeeding. This was in line with findings
from our BRAVO pilot study [51] and previous studies,
which showed an inverse relationship between breast-
feeding rate and the socioeconomic status [57–59]. The
decline rate of participants did not differ according to
the women’s socioeconomic status.
We believe that BRAVO is important for a number of
reasons. First, since it is performed in Indonesia and
strongly embedded in Indonesian maternal and child care,
its results with regard to possibilities for breastfeeding
optimization will be readily implementable locally. Second,
suggestions about the beneficial effects of breastfeeding on
cardiovascular and cardiometabolic risks later in life require
stronger supportive evidence [60]. We believe that the
BRAVO design presented herein can provide such evidence.
We conclude that a complex randomized trial like
BRAVO can be successfully conducted in a low-resource
setting like Indonesia, where solutions for low exclusive
breastfeeding proportions and evidence about both short
and long-term benefits are urgently needed.
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Trial status
The study is currently recruiting participants. By 19
April 2016, of the 1000 participants required, 853
women had been randomized. The estimated study com-
pletion, including the measurement of cardiovascular
outcomes, is July 2021.
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contains details about the study that are used to inform the women.
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